Neos Therapeutics, a late stage biotech developing extended release formulations of ADHD therapies, announced terms for its IPO on Monday.
The Grand Prairie, TX-based company plans to raise $60 million by offering 4.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, it would command a fully diluted market value of $220 million.
Neos Therapeutics, which was founded in 1994, plans to list on the NASDAQ under the symbol NEOS. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of July 20, 2015.
